Avilar Therapeutics
3 known investors
Avilar develops protein degrader drugs targeting extracellular and membrane-bound proteins, using a novel class called ATACs that harness endolysosomal degradation machinery. The company focuses on treating serious human diseases where currently undrugged extracellular proteins play a pathogenic role.